In recent months, the FAMHP has been repeatedly contacted regarding exceedances of donor quotas. These exceedances have been observed in some fertility centres as well as at national level. They concern both centre-specific donors and foreign donors, with or without the issuance of a Rapid Alert.
In line with the recovery plan, the FAMHP therefore aims to provide clear, transparent and contextualised explanations to facilitate the interpretation of the information published in the tables below.
It is important to emphasise that the presented data are based on information currently available, provided by fertility centres as part of inspections and biovigilance notifications. These figures are subject to change depending on new information and will be updated monthly.
In this context, the FAMHP cannot guarantee the completeness of the published data.
In addition, the FAMHP is actively continuing to update Fertidata, with the aim of obtaining a more exhaustive and accurate view of potential quota exceedances.
For any questions regarding the interpretation of general information, a Q&A is available on our website.
_____________________________________________
Rapid Alert
Global view of quota exceedance
_____________________________________________
Rapid Alert
The table below lists the 31 European Rapid Alerts where the Belgian legal limit of six women having had at least one child per donor, was exceeded (starting from 2022). Number of women who have had at least one child (treatment in Belgium).
The data presented in this table depend on the information provided by the fertility centres. This overview may be updated as further information becomes available. The published data therefore reflect the current situation and may be incomplete.
The number of pregnancies in this table does not necessarily correspond to confirmed pregnancies or births. There may be a discrepancy between the number of pregnancies, the number of children and the data available at the time of reporting (e.g. terminated pregnancies, ongoing pregnancies, new pregnancies).
It is important to note that blocking a donor does not prevent their gametes from being used for intended parents with the aim of conceiving a sibling of an already born child, based on a donation from that same donor. Although the number of families will no longer increase, the number of children within the same family may still change.
A Rapid Alert is a notification issued by a competent authority of a Member State of the European Union to inform other concerned Member States in the event of a health risk related to the use of tissues and cells. When a sperm donor is the subject of a Rapid Alert, this donor is permanently blocked and their sperm may no longer be used for the treatment of a new woman.
|
Donor X |
Donor sperm bank |
Other countries using the donor |
Number of women who have had at least one child in Belgium |
Number of children |
Number of Belgian fertility centres that received the donor’s sperm |
Year the Rapid Alert was issued |
Confirmed risk associated with use of the donor’s sperm |
|
Donor 1 |
ESB |
AT, DE, FI, FR, IE, IS, MT, NL, NO, PT, SE, XI |
7 |
9 |
6 |
2022 |
First blockage: Donor is a carrier of classic galactosemia.
Second blockage: The donor is carrier of Shwachman-Diamond syndrome. |
|
Donor 2 |
ESB |
BG, ES, GR, HU, IT, LV, PL |
20 |
20 |
13 |
2022 |
A pathogenic variant in the PHA gene has been identified in donor and he is a carrier |
|
Donor 3 |
ESB |
AT, CY, DE, FI, HU, IE, IS, MT, NL, NO, PT, SE, XI |
11 |
11 |
5 |
2022 |
Donor is a carrier of autosomal recessive inherited mild-to-moderate sensorineural |
|
Donor 4 |
ESB |
AT CY DE FI IE IS NL NO PT SE XI |
14 |
14 |
4 |
2022 |
The donor is a carrier of congenital disorder of glycosylation type Ia. |
|
Donor 5 |
ESB |
HU PL |
17 |
22 |
13 |
2023 |
Hip dysplasia in a donor confers an increased risk to his offspring. |
|
Donor 6 |
ESB |
GR IE PL |
9 |
11 |
8 |
2023 |
Donor is a carrier of c.10955delC(p.Pro3652Glnfs*2) in the PKHD1 gene. |
|
Donor 7 |
ESB |
PL |
11 |
11 |
9 |
2023 |
A deletion of exon 11-14 in the GLI2 gene in a donor child does confer an increased risk |
|
Donor 8 |
ESB |
ES GR HU |
8 |
10 |
8 |
2023 |
Donor is compound heterozygous for hemochromatosis. |
|
Donor 9 |
ESB |
ES GR IE IS IT LV PL |
8 |
8 |
7 |
2023 |
A duplication of 22q11 in the donor might confer an increased risk to his offspring. |
|
Donor 10 |
ESB |
AT DE FI FR GB IE IS NL NO PT SE |
12 |
16 |
5 |
2023 |
The genetic examination of the donor shows that he has a deletion in exon 16-29 of |
|
Donor 11 |
ESB |
AT CY DE EE FI FR GB IE IS NL NO PT SE |
10 |
11 |
4 |
2023 |
Donor investigation shows donor to be a carrier of 57kb deletion in the CTNS-gene. A 57 kb deletion in CTNS-gene in a donor child does confer an increased risk to donor’s offspring. Donor’s gametes are to be permanently blocked 08AUG2023. |
|
Donor 12 |
ESB |
BG CY DE ES GR HU IE IS NL PL |
38 |
53 |
14 |
2023 |
TP53 variant in a donor does confer an increased risk to donor’s offspring. |
|
Donor 13 |
ESB |
ES IT LV |
12 |
15 |
8 |
2023 |
The donor has been under investigation and the results have shown that he is a carrier |
|
Donor 14 |
ESB |
AT DE FI IE IS LU MT NL NO PT SE XI |
11 |
12 |
6 |
2023 |
Genetic testing showed that Donor is carrier of one of the two RAG2 variants. |
|
Donor 15 |
ESB |
AT DE GB IS NL NO PT SE |
7 |
8 |
4 |
2024 |
Isovaleric acidemia in a donor child, and subsequent genetic analysis showing that |
|
Donor 16 |
ESB |
HU |
10 |
10 |
10 |
2024 |
The donors Family history reveals that the PD has an unspecified hernia, |
|
Donor 17 |
ESB |
BG EE ES GR HU IE IT LV PL |
18 |
23 |
9 |
2024 |
MSH2 variant in a donor does confer an increased risk to donor’s offspring. |
|
Donor 18 |
ESB |
ES GR |
14 |
16 |
8 |
2024 |
The pathogenic variant ing the GAA gene was identified in the donor. |
|
Donor 19 |
ESB |
ES IT MT PL |
8 |
12 |
9 |
2024 |
Pathogenic MYBPC3 variant in a fetus and found in the donor confers an increased risk |
|
Donor 20 |
ESB |
BG CY ES GR HU IS IT LV PL RO |
21 |
24 |
10 |
2024 |
Cardiomyopathy in a donor child and subsequent diagnosis of heterozygosity of a |
|
Donor 21 |
ESB |
BG EE FR GR HU IS LT LV PL RO |
17 |
20 |
10 |
2025 |
Investigation of donor shows a 109kb deletion involving the NRXN1 gene. |
|
Donor 22 |
Cryos |
AT BG CY DE ES FR GB GR HU IE IT LU LV NL PL RO SE |
11 |
12 |
4* |
2025 |
Donor has been tested and carries a variant in USH2A. The risk of an affected child is |
|
Donor 23 |
ESB |
BG CY EE ES GR HU IT LV PL |
27 |
34 |
14 |
2025 |
The donor has been investigated and has an extraordinary genetic constellation since |
|
Donor 24 |
ESB |
AT CY DE FR GB GR IE IS NL PT SE |
10 |
10 |
5 |
2025 |
We can conclude that the donor has a genotype with a deletion of SMN1 on one |
|
Donor 25 |
ESB |
BG CY CZ EE ES GR HU IE IS IT LT LU PL RO |
19 |
27 |
12 |
2025/2026 |
First blockade : The donor is found to be a healthy carrier of a pathogenic variant in the CYP21A2 gene. Non-Classical congenital adrenal hyperplasia (CAH) due to compound heterozygous mutations in the CYP21A2 gene in a donor child confers an increased risk to donor's offspring. His gametes are permanently blocked. Second blockade : Gametes of the donor were previously pemanently blocked because |
|
Donor 26 |
ESB |
FR GR HU IS LV PL |
9 |
9 |
8 |
2025 |
Deletion of the CYP21A2 gene in a donor does confer an increased risk to donor’s |
|
Donor 27 |
ESB |
ES IT NL PL |
12 |
15 |
10* |
2025 |
A pathogenic (class V) genetic variant was observed in the Thyroglobulin (TG) gene. |
|
Donor 28 |
ESB |
BG CY DE ES FR GR HU IE IS IT LT LU LV PL RO SE XI |
22 |
29 |
10 |
2025 |
The donor is a carrier of Metachromatic leukodystrophy (MLD), since a pathogenic |
|
Donor 29 |
ESB |
BG CY EE ES FR GR HU IE IS IT LV PL |
14 |
22 |
10 |
2025 |
The donor has been under investigation and the results have shown that he is a |
|
Donor 30 |
ESB |
BG CY EE FR GR HU IS LV PL RO |
10 |
11 |
10 |
2025 |
The CHEK2 variant c1100delC found in the donor confers an increased risk to donor's |
|
Donor 31 |
ESB |
CY DE ES FI FR GR IE IT LU MT NL PL PT |
28 |
31 |
10 |
2026 |
A donor child has been diagnosed with Carnitine palmitoyltransferase type 2 deficiency, |
* private recipient(s)
2. Global view of quota exceendance
The table below shows all the quota exceedances of which the FAMHP is currently aware. It also includes the Rapid Alerts mentioned above.
These situations have been brought to the agency's attention through various channels:
- via biovigilance notifications that did not result in a Rapid Alert,
- during inspections,
- or following voluntary reports from fertility centres.
The table sets out all exceedances recorded per donor, regardless of the number of centres involved.
When an exceedance relating to a donor has been identified within a single centre — for example when that centre has used the same donor for more than six families — this information is explicitly stated in the last column (‘quota exceedance within a centre’).
An empty column means that the exceedance is spread across several centres, with no individual centre having exceeded the limit of six families.
This overview contributes to increased transparency, consistent monitoring of identified situations, and an overall assessment of compliance with current quotas.
| # | Rapid alert/ Other notifications |
Internal Donor ID |
Origin | Nbr families |
Nbr children |
Nbr institution |
Notification year |
Quota exceedance within a centre |
| 1 | Rapid Alert | 1 | ESB | 7 | 9 | 6 | 2022 | |
| 2 | Rapid Alert | 2 | ESB | 20 | 20 | 13 | 2022 | |
| 3 | Rapid Alert | 3 | ESB | 11 | 11 | 5 | 2022 | |
| 4 | Rapid Alert | 4 | ESB | 14 | 14 | 4 | 2022 | |
| 5 | Rapid Alert | 5 | ESB | 17 | 22 | 13 | 2023 | |
| 6 | Rapid Alert | 6 | ESB | 9 | 11 | 8 | 2023 | |
| 7 | Rapid Alert | 7 | ESB | 11 | 11 | 9 | 2023 | |
| 8 | Rapid Alert | 8 | ESB | 8 | 10 | 8 | 2023 | |
| 9 | Rapid Alert | 9 | ESB | 8 | 8 | 7 | 2023 | |
| 10 | Rapid Alert | 10 | ESB | 12 | 16 | 5 | 2023 | |
| 11 | Rapid Alert | 11 | ESB | 10 | 11 | 4 | 2023 | |
| 12 | Rapid Alert | 12 | ESB | 38 | 53 | 14 | 2023 | Centre 11 |
| 13 | Rapid Alert | 13 | ESB | 12 | 15 | 8 | 2023 | |
| 14 | Rapid Alert | 14 | ESB | 11 | 12 | 6 | 2023 | |
| 15 | Rapid Alert | 15 | ESB | 7 | 8 | 4 | 2024 | |
| 16 | Rapid Alert | 16 | ESB | 10 | 10 | 10 | 2024 | |
| 17 | Rapid Alert | 17 | ESB | 18 | 23 | 9 | 2024 | |
| 18 | Rapid Alert | 18 | ESB | 14 | 16 | 8 | 2024 | |
| 19 | Rapid Alert | 19 | ESB | 8 | 12 | 9 | 2024 | |
| 20 | Rapid Alert | 20 | ESB | 21 | 24 | 10 | 2024 | |
| 21 | Rapid Alert | 21 | ESB | 17 | 20 | 10 | 2025 | |
| 22 | Rapid Alert | 22 | Cryos | 11 | 12 | 4* | 2025 | |
| 23 | Rapid Alert | 23 | ESB | 27 | 34 | 14 | 2025 | |
| 24 | Rapid Alert | 24 | ESB | 10 | 10 | 5 | 2025 | |
| 25 | Rapid Alert | 25 | ESB | 19 | 27 | 12 | 2025/2026 | |
| 26 | Rapid Alert | 26 | ESB | 9 | 9 | 8* | 2025 | |
| 27 | Rapid Alert | 27 | ESB | 12 | 15 | 10* | 2025 | |
| 28 | Rapid Alert | 28 | ESB | 22 | 29 | 10 | 2025 | |
| 29 | Rapid Alert | 29 | ESB | 14 | 22 | 10 | 2025 | |
| 30 | Rapid Alert | 30 | ESB | 10 | 11 | 10 | 2025 | |
| 31 | Rapid Alert | 31 | Cryos | 28 | 31 | 10 | 2026 | Centre 11/Centre 25 |
| 32 | Rapid Alert | R1 | ESB | 16 | 20 | 2012 | ||
| 33 | Rapid Alert | R2 | Cryos | > 6 | 2016 | Centre 9 | ||
| 34 | Rapid Alert | R3 | Cryos | > 6 | 2018 | Centre 25 | ||
| 35 | Rapid Alert | R4 | Cryos | > 6 | 2019 | Centre 25 | ||
| 36 | Rapid Alert | R5 | Cryos | > 6 | 2019 | Centre 25 | ||
| 37 | Rapid Alert | R6 | ESB | > 6 | 2019 | Centre 7/Centre 23/ Centre 25 | ||
| 38 | Rapid Alert | R7 | Cryos | > 6 | 2019 | Centre 25/Centre 9 | ||
| 39 | Rapid Alert | R8 | Cryos | > 6 | 2019 | Centre 25 | ||
| 40 | Rapid Alert | R9 | Cryos | > 6 | 2019 | Centre 25 | ||
| 41 | Rapid Alert | R10 | ESB | > 6 | 2020 | |||
| 42 | Rapid Alert | R11 | ESB | 7 | 2020 | |||
| 43 | Rapid Alert | R12 | ESB | 11 | 2020 | |||
| 44 | Rapid Alert | R13 | ESB | 8 | 2020 | |||
| 45 | Rapid Alert | R14 | Cryos | 17 | 2020 | Centre 25/ Centre 9 |
||
| 46 | Rapid Alert | R15 | Cryos | 8 | 2020 | |||
| 47 | Rapid Alert | R16 | Cryos | 8 | 2020 | |||
| 48 | Rapid Alert | R17 | ESB | > 6 | 2020 | |||
| 49 | Rapid Alert | R18 | ESB | 9 | 2020 | |||
| 50 | Rapid Alert | R19 | ESB | 33 | 2021 | |||
| 51 | Rapid Alert | R20 | ESB | 15 | 2021 | |||
| 52 | Rapid Alert | R21 | ESB | 11 | 2021 | |||
| 53 | Rapid Alert | R22 | ESB | 10 | 2021 | |||
| 54 | Rapid Alert | R23 | ESB | 7 | 2021 | |||
| 55 | Internal donnor | B1 | Own bank | 16 | 2019 | Centre 25 | ||
| 56 | Internal donnor | B2 | Own bank | 8 | 2021 | Centre 25 | ||
| 57 | Internal donnor | B3 | Own bank | 7 | 2022 | Centre 25 | ||
| 58 | Internal donnor | B4 | Own bank | 9 | 2022 | Centre 25 | ||
| 59 | Internal donnor | B5 | Own bank | 10 | 2023 | Centre 25 | ||
| 60 | Internal donnor | B6 | Own bank | 7 | 2023 | Centre 25 | ||
| 61 | Internal donnor | B7 | Own bank | 8 | 2024 | Centre 25 | ||
| 62 | Internal donnor | B8 | Own bank | 7 | 2025 | Centre 30 | ||
| 63 | Internal donnor | B9 | Own bank | 13 | 2025 | Centre 25 | ||
| 64 | Internal donnor | B10 | Own bank | 8 | 2025 | Centre 9 | ||
| 65 | Internal donnor | B11 | Own bank | 25 | 2026 | Centre 25 | ||
| 66 | Internal donnor | B12 | Own bank | 7 | 2026 | Centre 10 | ||
| 67 | European donnor without RA | E1 | ESB | > 6 | 2025 | |||
| 68 | European donnor without RA | E2 | ESB | > 6 | 2025 | |||
| 69 | European donnor without RA | E3 | ESB | > 6 | 2025 | |||
| 70 | European donnor without RA | E4 | ESB | > 6 | 2025 | |||
| 71 | European donnor without RA | E5 | ESB | > 6 | 2025 | |||
| 72 | European donnor without RA | E6 | ESB | > 6 | 2025 | |||
| 73 | European donnor without RA | E7 | ESB | > 6 | 2025 | |||
| 74 | European donnor without RA | E8 | ESB | > 6 | 2025 | |||
| 75 | European donnor without RA | E9 | ESB | > 6 | 2025 | |||
| 76 | European donnor without RA | E10 | ESB | > 6 | 2025 | |||
| 77 | European donnor without RA | E11 | ESB | > 6 | 2025 | |||
| 78 | European donnor without RA | E12 | ESB | > 6 | 2025 | |||
| 79 | European donnor without RA | E13 | ESB | > 6 | 2025 | |||
| 80 | European donnor without RA | E14 | ESB | > 6 | 2025 | |||
| 81 | European donnor without RA | E15 | ESB | > 6 | 2025 | |||
| 82 | European donnor without RA | E16 | ESB | > 6 | 2025 | |||
| 83 | European donnor without RA | E17 | Cryos | > 6 | 2026 | |||
| 84 | European donnor without RA | E18 | ESB | > 6 | 2026 | |||
| 85 | European donnor without RA | E19 | ESB | > 6 | 2026 | |||
| 86 | European donnor without RA | E20 | ESB | > 6 | 2026 | |||
| 87 | European donnor without RA | E21 | ESB | > 6 | 2026 | |||
| 88 | European donnor without RA | E22 | Cryos | 11 | 2025 | Centre 9 | ||
| 89 | European donnor without RA | E23 | Cryos | 10 | 2025 | Centre 9 | ||
| 90 | European donnor without RA | E24 | Cryos | 10 | 2025 | Centre 9 | ||
| 91 | European donnor without RA | E25 | Cryos | 9 | 2025 | Centre 9 | ||
| 92 | European donnor without RA | E26 | ESB | 7 | 2025 | Centre 11 | ||
| 93 | European donnor without RA | E27 | ESB | 8 | 2025 | Centre 11 | ||
| 94 | European donnor without RA | E28 | Cryos | 7 | 2025 | Centre 11 |
* private recipient(s)
- A. Foreign donor with Rapid Alert (issued between 2022 and today)
Donor identified by a number (e.g. donor 5). - B. Foreign donor with Rapid Alert (issued prior to 2022)
Donor identified by the letter ‘R’ followed by a number (e.g. donor R5). - C. Foreign donor without Rapid Alert
Donor identified by the letter ‘E’ followed by a number (e.g. donor E5).
⚠️ If a Rapid Alert is issued at a later stage, the donor is removed from this category and reclassified into category A. - D. Centre-specific donor
Donor identified by the letter ‘B’ followed by a number (e.g. donor B5).